GenomOncology is the leading provider of software solutions for the precision oncology market. 


Review our latest Press Releases and Publications to see how we are helping researchers and clinicians enhance their workflow, scale their reporting capabilities, and improve patients lives everyday. 

We are continuously improving our solutions to fit the evolving needs of our clients.


June 9, 2021

The Pancreatic Cancer Action Network Increases Biomarker-Driven Clinical Trial Matching Capabilities by nearly 300% with GenomOncology 

GenomOncology announced today that the Pancreatic Cancer Action Network (PanCAN) has chosen to upgrade to GenomOncology’s Precision Decision to further enhance the free clinical trial matching services it offers to pancreatic cancer patients.

April 22, 2021

Medical College of Wisconsin Streamlines Molecular Pathology Lab Processes with GenomOncology Pathology Workbench

The Medical College of Wisconsin (MCW) Genomic Sciences & Precision Medicine Center (GSPMC) Precision Medicine Lab (PML) is implementing the newest version of GenomOncology’s (GO) Pathology Workbench to further strengthen the efficiencies of its molecular oncology offerings.

April 6, 2021

Diagnostic Laboratory Services, Inc. (DLS) Launches New Precision Medicine Program with GenomOncology’s Pathology Workbench

GenomOncology, LLC announced today that Diagnostic Laboratory Services, Inc. (DLS) has selected the GenomOncology (GO) Pathology Workbench to streamline variant analysis for their next generation sequencing (NGS) in support of the Queen’s Medical Center’s precision medicine program.

March 16, 2021

New technology matching patients genetic testing with available clinical trials nationwide arrives at University Hospitals

GenomOncology announced today that University Hospitals (UH) Seidman Cancer Center has selected GenomOncology’s Precision Decision and GO Connect solutions to help scale their precision oncology program. The proprietary platform streamlines a complicated process in order to help both patients and doctors.

October 29, 2020

GenomOncology Releases igniteIQ, a Data Extraction Solution

GenomOncology announced today the release of their newest product, igniteIQ. igniteIQ is a solution designed to efficiently extract clinically-relevant data from scanned or digital PDF reports, currently NGS and pathology reports, and convert that data to discrete data elements. Through automation and quality assurance, igniteIQ streamlines data validation and analysis to create actionable information. 

October 14, 2020

GenomOncology Releases New Version of Pathology Workbench Tool, Optimized for Large Panels and Higher Sample Throughput

GenomOncology announced today the release of their newest version of the GenomOncology (GO) Pathology Workbench solution, which is optimized for larger panels (such as Illumina's TSO500), higher sample throughput, and the interpretation of copy numbers and structural variants by Next Generation Sequencing (NGS).

September 29, 2020

The University of Alabama at Birmingham (UAB) Selects GenomOncology's Pathology Workbench and GenomAnalytics for Molecular Pathology Lab Expansion

GenomOncology announced today that The University of Alabama at Birmingham (UAB) has selected GenomOncology's Pathology Workbench and GenomAnalytics to help scale their molecular pathology lab's test volume and analysis.

May 20, 2020

The Pancreatic Cancer Action Network Implements Genomoncology’s Clinical Trial Matching Solution to Support Biomarker-Driven Clinical Trial Searches

Patient advocacy organization, Pancreatic Cancer Action Network (PanCAN) and healthcare software company GenomOncology, LLC announce PanCAN’s implementation of GenomOncology’s Clinical Trial Matching solution that will streamline the organization’s biomarker-driven clinical trial matching process as part of their Patient Services program.

April 8, 2020

Diagnostic Laboratory Services, Inc. selects GenomOncology's Pathology Workbench for new Precision Medicine program

GenomOncology, LLC announced today that Diagnostic Laboratory Services, Inc. (DLS) has selected the GenomOncology Pathology Workbench to provide analysis services for the assay for their new Precision Medicine program

July 12, 2019

Improved website for

My Cancer Genome launched

Vanderbilt-Ingram Cancer Center and GenomOncology LLC announce the launch of the newly redesigned and improved My Cancer Genome website. The new site showcases the breadth and depth of curated content from My Cancer Genome.

June 6, 2019

GenomOncology announces participation in Biden Cancer Initiative’s OCTIC

GenomOncology is excited to be a part of the Biden Cancer Initiative’s Oncology Clinical Trial Information Commons (OCTIC), joining forces with 8 other organizations to improve clinical trial matching and enrollment for patients.

May 2, 2019

Northwestern Memorial Healthcare Chooses GenomOncology Pathology Workbench for their NGS Clinical Analysis

GenomOncology announces Northwestern Memorial Healthcare has chosen the GenomOncology Pathology Workbench system as part of its clinical analysis process for their latest Oncomine Comprehensive NGS Assay. The Pathology Workbench enables comprehensive variant filtering and flexible reporting to help scale Northwestern's process.


26, 2018

GenomOncology Announces Brad Wertz as Chairman and CEO

GenomOncology announced today that Brad Wertz will assume the role of Chairman and Chief Executive Officer (CEO) as of January 1, 2019. Mr. Wertz has been a founding investor and chairman of the board since the company's...


28, 2018

GenomOncology Enables Novel Decision Support for AML at the Nashville Veterans Affairs Hospital

GenomOncology LLC, a leading provider of end-to-end precision medicine solutions in oncology, has developed a solution to integrate IHC, FISH, NGS and Karyotyping in order to provide therapy and clinical trial recommendations...


23, 2018

GenomOncology Announces GO Pathology Workbench in use by Emory Healthcare 

GenomOncology today announced that Emory Healthcare is now using GenomOncology's GO Pathology Workbench system as part of its clinical reporting process, enabling the return of clinical reports to ordering physicians more rapidly...


23, 2018

GenomOncology adds Jonathan Seaton, former SVP Corporate & Business Development At Illumina, to its Board Of Directors

GenomOncology LLC, a leading provider of end-to-end precision medicine solutions in oncology, has added Jonathan Seaton most recently Senior Vice President for Corporate & Business Development at Illumina to its Board of Directors.


07, 2018

Fluidigm Partners with GenomOncology to Provide a Comprehensive Immuno-oncology Gene Expression Solution

Fluidigm Corporation (NASDAQ:FLDM) and GenomOncology today announced an expanded Immuno-Oncology Gene Expression Workflow to accelerate the development of checkpoint immunotherapies and the identification of potential predictive biomarker signatures for therapeutic...